Latest News for: safety profile

Edit

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (Form 8-K) (Corbus Pharmaceuticals Holdings Inc)

Public Technologies 11 Dec 2025
for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss • CRB-913 was safe and well-tolerated across all doses studied.
Edit

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile (Form 8-K) (Senti Biosciences Inc)

Public Technologies 09 Dec 2025
) Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile.
Edit

Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile

Pharmiweb 08 Dec 2025
The combination continues to demonstrate an excellent safety profile ... The encouraging safety profile and clear efficacy signals support bexmarilimab's advancement into a randomized Phase 3 ...
Edit

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 ...

The Galveston Daily News 02 Dec 2025
SAN DIEGO--(BUSINESS WIRE)--Dec 1, 2025-- ....
Edit

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study (Form 8-K) (Pasithea Therapeutics Corporation)

Public Technologies 25 Nov 2025
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study ... --Favorable Safety Profile.
Edit

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum ...

Citizen Tribune 18 Nov 2025
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating ...
Edit

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) (Form 8-K) (Lipocine Inc)

Public Technologies 18 Nov 2025
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) ● Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned.
Edit

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

PR Newswire 18 Nov 2025
"We are encouraged by the safety profile observed in our clinical experience to date with our oral product candidate comprising GABAA positive allosteric modulating neuroactive steroid with low sedation," said Mahesh Patel, CEO of Lipocine.
Edit

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile (Vir Biotechnology Inc)

Public Technologies 09 Nov 2025
The combination also showed alanine aminotransferase (ALT) reductions over time and a favorable safety pro le ... e cacy and safety data needed for potential submission to global regulatory agencies ... unexpected safety or.
Edit

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of

Enid News & Eagle 08 Nov 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov.
Edit

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a ...

Nasdaq Globe Newswire 08 Nov 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc ... .
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable ...

Nasdaq Globe Newswire 04 Nov 2025
Pratteln, Switzerland, November 4, 2025 – Santhera Pharmaceuticals (SIX ... .
Edit

Five-year data of AGAMREE� (vamorolone) in patients with DMD show improved safety profile with comparable ...

Nasdaq Globe Newswire 04 Nov 2025
Ad hoc announcement pursuant to Art. 53 LR ... .
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Pharmiweb 04 Nov 2025
Importantly, the data continue to support a differentiated safety and tolerability profile versus traditional corticosteroids ... of treatment and showed a good safety and tolerability profile [2, 5].
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids (Santhera Pharmaceuticals Holding AG)

Public Technologies 04 Nov 2025
53 LR Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids ... and tolerability profile [2, 5].

Article Search

tools
×
×
×
×